Precede Biosciences

Precede Biosciences is an early-stage diagnostics company founded in 2021, focused on epigenomic liquid biopsy. Its proprietary platform analyzes cell-free chromatin and DNA methylation from just 1mL of plasma to provide a genome-wide view of gene and pathway activity, offering a novel tool for both drug development and clinical diagnostics. The company operates with a dual business model, partnering with pharmaceutical developers while also advancing its own diagnostic tests. Led by a team with deep expertise in translational medicine, computational biology, and diagnostics, Precede aims to significantly expand the reach and utility of precision medicine.

First-in-class liquid biopsy platform that profiles circulating chromatin and the DNA methylome from 1mL of plasma to provide a genome-wide view of gene promoter, enhancer, and CpG island activity, revealing dynamic gene and pathway activation.

Precede competes in the liquid biopsy space but is differentiated by its focus on epigenomics (chromatin accessibility and methylation) rather than circulating tumor DNA (ctDNA) mutations. This positions it against other epigenomic profiling companies and broader diagnostic firms, but its comprehensive, genome-wide platform from a standard blood draw is a claimed first-in-class advantage.